BIOMAT Database Logo BIOMAT Database Logo

Raltegravir for postexposure prophylaxis following occupational exposure to HIV. 2008

Marc O Siegel, and Virginia L Kan, and Debra A Benator

UI MeSH Term Description Entries
D008297 Male Males
D011760 Pyrrolidinones A group of compounds that are derivatives of oxo-pyrrolidines. A member of this group is 2-oxo pyrrolidine, which is an intermediate in the manufacture of polyvinylpyrrolidone. (From Merck Index, 11th ed) Pyrrolidinone,Pyrrolidone,Pyrrolidones
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068898 Raltegravir Potassium A pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION. Isentress,MK 0518,MK-0518,MK0518,Raltegravir,0518, MK,Potassium, Raltegravir
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016273 Occupational Exposure The exposure to potentially harmful chemical, physical, or biological agents that occurs as a result of one's occupation. Exposure, Occupational,Exposures, Occupational,Occupational Exposures
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017758 Infectious Disease Transmission, Patient-to-Professional The transmission of infectious disease or pathogens from patients to health professionals or health care workers. It includes transmission via direct or indirect exposure to bacterial, fungal, parasitic, or viral agents. Disease Transmission, Patient-to-Professional,Transmission, Patient-to-Professional,Disease Transmission, Patient-Professional,Infection Transmission, Patient-Professional,Pathogen Transmission, Patient-Professional,Patient-to-Professional Disease Transmission,Patient-to-Professional Transmission,Transmission, Patient-Professional,Disease Transmission, Patient Professional,Disease Transmission, Patient to Professional,Infection Transmission, Patient Professional,Infectious Disease Transmission, Patient to Professional,Pathogen Transmission, Patient Professional,Patient to Professional Disease Transmission,Patient to Professional Transmission,Patient-Professional Disease Transmission,Patient-Professional Infection Transmission,Patient-Professional Infection Transmissions,Patient-Professional Pathogen Transmission,Patient-Professional Transmission,Transmission, Patient Professional,Transmission, Patient to Professional,Transmission, Patient-Professional Infection,Transmission, Patient-Professional Pathogen
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Marc O Siegel, and Virginia L Kan, and Debra A Benator
Postexposure prophylaxis for occupational exposure to HIV.
November 1999, JAMA,
Marc O Siegel, and Virginia L Kan, and Debra A Benator
Postexposure prophylaxis following HIV exposure.
April 1999, JAMA,
Marc O Siegel, and Virginia L Kan, and Debra A Benator
Postexposure prophylaxis following HIV exposure.
April 1999, JAMA,
Marc O Siegel, and Virginia L Kan, and Debra A Benator
Postexposure prophylaxis after an occupational exposure to HIV.
January 1997, The Journal of the Association of Nurses in AIDS Care : JANAC,
Marc O Siegel, and Virginia L Kan, and Debra A Benator
Postexposure prophylaxis for HIV following sexual exposure.
July 2010, Current opinion in HIV and AIDS,
Marc O Siegel, and Virginia L Kan, and Debra A Benator
Occupational exposure to HIV: considerations for postexposure prophylaxis and prevention.
March 1999, The Nursing clinics of North America,
Marc O Siegel, and Virginia L Kan, and Debra A Benator
[Postexposure prophylaxis after occupational exposure to HBV, HCV and HIV].
February 2004, Der Radiologe,
Marc O Siegel, and Virginia L Kan, and Debra A Benator
Should emergency departments offer postexposure prophylaxis for non-occupational exposure to HIV?
January 2003, CJEM,
Marc O Siegel, and Virginia L Kan, and Debra A Benator
Postexposure prophylaxis for nonoccupational HIV exposure.
November 2004, The AIDS reader,
Marc O Siegel, and Virginia L Kan, and Debra A Benator
Updated guideline for occupational postexposure prophylaxis for HIV.
February 2008, AIDS clinical care,
Copied contents to your clipboard!